Author

R. S. Lokey

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Assay:bulk RNA-seq· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Approach:deep learning· 1 Research Focus:differential expression· 1 Approach:experimental assay· 1 Assay:imaging· 1

Frequent Co-Authors

W. Bray· 2 shared A. J. Smith· 1 shared A. Lohith· 1 shared A. Shaikh· 1 shared C. Lagisetti· 1 shared E. A. McMillan· 1 shared F. Carnevale· 1 shared J. B. MacMillan· 1 shared

Activity by Year

2019-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 27 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersPharmacology & Toxicology

W. Bray

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

High-Throughput Functional Annotation of Natural Products by Integrated Activity Profiling

J. B. MacMillan, R. G. Linington, S. K. Hight, R. S. Lokey, W. Bray, K. Kurita, A. Shaikh, J. Haeckl, S. La, A. Lohith, E. A. McMillan, M. A. White, T. N. Clark, J. Lee, F. Carnevale, , S. Wei

This paper introduces a platform integrating phenotypic screening and metabolomics to improve mechanism of action prediction for natural products, leading to the discovery of novel bioactive compounds.

bioRxiv · Jun 8, 2022Pharmacology & Toxicology

An Exon Skipping Screen Identifies Antitumor Drugs That Are Potent Modulators of Pre-mRNA Splicing, Suggesting New Therapeutic Applications

Y. Shi, W. Bray, A. J. Smith, W. Zhou, J. Calaoagan, C. Lagisetti, L. Sambucetti, P. Crews, R. S. Lokey, T. R. Webb

The paper identifies antitumor drugs that modulate pre-mRNA splicing through a screening assay, revealing new therapeutic applications and SF3B1 antagonists.

bioRxiv · Mar 21, 2019Cancer Biology